REATA PHARMACEUTICALS INC-A (RETA)
US75615P1030 - Common Stock
Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
/PRNewswire/ -- TO: All persons and entities who, during the period between November 14, 2016 through December 8, 2021 inclusive, purchased or otherwise...
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shareholder Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/04/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Reata Pharmaceuticals, Inc.
Biogen Completes Acquisition of Reata Pharmaceuticals
Reta shareholders clear buyout deal with Biogen (NASDAQ:RETA)
Reata Pharmaceuticals (RETA) said that its shareholders approved its previously disclosed acquisition by Biogen (BIIB) at a special meeting on Thursday. Read more here.
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, TRHC, VRTV, CTG
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
First Week of January 2026 Options Trading For Reata Pharmaceuticals (RETA)
Notable Monday Option Activity: SPLK, FUBO, RETA
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
Buying a biotech is a good move, but it might not be enough to entice investors.
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SOVO, NEWR, RETA, AMNB
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
The 7 Most Promising Momentum Stocks to Own Now
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.
The 3 Most Promising Pharma Stocks to Own Now
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CCF, SCU, AMNB, RETA
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Notable Friday Option Activity: BYND, HIBB, RETA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CELL, AEL, RETA
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Sanofi was mystery bidder in Reata Pharma bidding war - report
Sanofi (SNY) was the other buyer in the recent bidding war for Reata Pharmaceuticals (RETA), narrowly losing out to Biogen's $7.3 billion offer
Sanofi Was Mystery Bidder That Lost Reata to Biogen
Biogen Inc. narrowly beat out Sanofi SA to clinch its $7.3 billion acquisition of Reata Pharmaceuticals, according to people familiar with the matter.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, NEWR, RETA, SOVO
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
With an Acquisition on the Way, Is Biogen Stock a Buy?
Can the biotech finally get back in the good graces of investors?
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEWR, RETA, INPX, PACW
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, EQRX, RVMD
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now.
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen also recently announced a plan to cut costs and focus investment on high-growth areas.
Could This Stock Be the Next Biotech Buyout?
A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next.